Immunological Synapse Quality Prediction for CAR T Cell Effectiveness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the effectiveness of chimeric antigen receptor (CAR) T cells are time-consuming, labor-intensive, costly, and inaccurate, lacking a cost-effective way to predict their quality and safety before clinical trials.
Innovation Solution
A method involving a planar lipid bilayer with labeled tumor antigens is used to measure the quality of the immunological synapse between CAR T cells and antigens through microscopy techniques like confocal or super-resolution microscopy, assessing parameters such as phosphorylated zeta chain, F-actin, perforin, pZAP70, and Lck accumulation to predict CAR T cell effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional tools for immunological analyses are used to evaluate CAR T cell quality and effectiveness, then comprehensive assessment can be obtained, but the process becomes time-consuming, labor-intensive, costly, and inaccurate
Solution Approach 1:
The patent extracts and focuses on the critical immunological synapse formation as the key indicator of CAR T cell effectiveness. By isolating this specific aspect from comprehensive immunological analysis, the method achieves accurate prediction of CAR T cell quality without requiring time-consuming complete immune system evaluation. The synapse formation metrics (clustering, signaling molecule accumulation) are measured directly to predict effectiveness, eliminating unnecessary intermediate steps.
Solution Approach 2:
The patent performs preliminary assessment of CAR T cell quality by evaluating immunological synapse formation before clinical deployment. By measuring synapse characteristics (antigen clustering, phosphorylated signaling molecules, cytoskeletal reorganization) in advance, the method predicts which CAR T cell products will be effective, preventing wasted time on ineffective candidates during and after clinical trials.
2Measurement precision
If multiple assays are performed to accurately measure immunological synapse quality, then prediction accuracy improves, but the complexity and cost of the methodology increases
Solution Approach 1:
The patent combines multiple measurement approaches (fluorescence microscopy, confocal imaging, signal transduction assays) into a unified immunological synapse quality evaluation framework. By merging these techniques to assess different aspects of synapse formation (structural, signaling, functional) simultaneously, the method achieves comprehensive and accurate quality prediction without requiring separate complex assay systems for each parameter.
Solution Approach 2:
The patent develops a universal immunological synapse quality assessment methodology that can evaluate different CAR T cell products using the same framework. The synapse quality metrics (clustering index, signaling molecule accumulation, cytoskeletal organization) serve as universal indicators applicable across various CAR targets and T cell sources, reducing the need for product-specific complex assay development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a precise, cost-effective prediction of CAR T cell effectiveness by evaluating the quality of the immunological synapse, enabling better assessment and development of CAR T therapies.
Implementation Method 1
providing a planar lipid bilayer comprising a plurality of labeled tumor antigens
Implementation Method 2
performing at least three of (1) to (6) comprises using microscopy comprising confocal microscopy
Implementation Method 3
epifluorescence microscopy
Implementation Method 4
measuring the quality of an immunological synapse between CARs and the antigen
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A
AI summary
Embodiments of the disclosure concern methods of determining the effectiveness of immune cells, such as T cells, with particular chimeric antigen receptors. In specific embodiments, a synapse between the CAR and the tumor antigen is measured for structure, signaling, and functionality by imaging. As such, the quality of the synapse is determined and positively correlates with effectiveness of the particular CAR immune cells.